Central African RepublicTuberculosis profile
Population  2017 4.7 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.2 (1.8–4.9) 68 (38–105)
Mortality (HIV+TB only) 2.7 (1.4–4.4) 58 (31–94)
Incidence  (includes HIV+TB) 20 (13–28) 423 (274–604)
Incidence (HIV+TB only) 6.2 (3.3–10) 134 (72–214)
Incidence (MDR/RR-TB)** 0.15 (0.084–0.23) 3.2 (1.8–4.9)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 1.3 (1.2–1.4) 6.3 (4.9–7.6) 7.5 (5.7–9.4)
Males 1.4 (1.3–1.6) 11 (7.6–14) 12 (8.4–16)
Total 2.7 (2.3–3.1) 17 (11–23) 20 (13–28)
TB case notifications, 2017  
Total cases notified 9 819
Total new and relapse 9 664
          - % tested with rapid diagnostics at time of diagnosis 3%
          - % with known HIV status 77%
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 66%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 49% (34–76)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.31 (0.16–0.48)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 2 098 28%
          - on antiretroviral therapy 1 541 73%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  91
(0–190)
Estimated % of TB cases with MDR/RR-TB 0.4% (0–2.2) 14% (10–18)  
% notified tested for rifampicin resistance 0% 62% 268
MDR/RR-TB cases tested for resistance to second-line drugs   2
Laboratory-confirmed cases MDR/RR-TB: 93, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 86, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 78% 5 312
Previously treated cases, excluding relapse, registered in 2016 79% 186
HIV-positive TB cases registered in 2016 73% 2 053
MDR/RR-TB cases started on second-line treatment in 2015 88% 41
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 0%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions) 1.9
Funding source: 14% domestic, 53% international, 32% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-10-17 Data: www.who.int/tb/data